AZ Rivierenland

At AZ Rivierenland in Rumst, clinical research in anesthesiology focuses on improving pain control and recovery after surgery, especially for patients scheduled for shoulder operations and inguinal hernia repair. These studies are designed to test better ways to relieve postoperative pain and support smoother healing.

• Evaluating perineural dexmedetomidine to extend pain relief after an interscalene plexus block
• Comparing TAP block with local wound infiltration for laparoscopic inguinal hernia surgery
• Assessing locoregional techniques to improve postoperative analgesia

Overall, this research area centers on finding more effective analgesic strategies that can reduce discomfort and improve patient experience after operative procedures.

The site also supports studies in digestive system diseases, with a strong focus on colon cancer. One major line of research examines whether acetylsalicylic acid can improve survival and reduce recurrence in patients with stage II and III disease, reflecting interest in better long-term treatment options.

• Studying colon carcinoma outcomes after surgery
• Testing whether aspirin can improve overall survival in colon cancer
• Exploring approaches to lower the risk of cancer recurrence

This work aims to evaluate treatment effectiveness and help define supportive strategies for people living with colorectal cancer.

Research in neoplasms at AZ Rivierenland includes studies in neuroendocrine tumours, where investigators are examining how ongoing treatment can be managed when the disease progresses. The purpose is to better understand whether continuing or stopping standard therapy may influence patient outcomes and quality of life.

• Investigating treatment choices after progression in neuroendocrine tumour patients
• Assessing survival and symptom-related outcomes during second-line therapy
• Looking at patient well-being alongside disease control

These studies combine oncology and patient-reported outcomes to guide more personalized care for people with advanced neuroendocrine cancer.